1. Home
  2. IOVA vs DHC Comparison

IOVA vs DHC Comparison

Compare IOVA & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • DHC
  • Stock Information
  • Founded
  • IOVA 2007
  • DHC 1998
  • Country
  • IOVA United States
  • DHC United States
  • Employees
  • IOVA N/A
  • DHC N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • DHC Real Estate Investment Trusts
  • Sector
  • IOVA Health Care
  • DHC Real Estate
  • Exchange
  • IOVA Nasdaq
  • DHC Nasdaq
  • Market Cap
  • IOVA 975.1M
  • DHC 856.4M
  • IPO Year
  • IOVA N/A
  • DHC N/A
  • Fundamental
  • Price
  • IOVA $2.31
  • DHC $4.17
  • Analyst Decision
  • IOVA Buy
  • DHC Strong Buy
  • Analyst Count
  • IOVA 11
  • DHC 1
  • Target Price
  • IOVA $11.90
  • DHC $5.50
  • AVG Volume (30 Days)
  • IOVA 10.3M
  • DHC 643.0K
  • Earning Date
  • IOVA 11-06-2025
  • DHC 11-03-2025
  • Dividend Yield
  • IOVA N/A
  • DHC 0.98%
  • EPS Growth
  • IOVA N/A
  • DHC N/A
  • EPS
  • IOVA N/A
  • DHC N/A
  • Revenue
  • IOVA $241,525,000.00
  • DHC $1,522,835,000.00
  • Revenue This Year
  • IOVA $68.14
  • DHC $4.05
  • Revenue Next Year
  • IOVA $56.64
  • DHC $3.08
  • P/E Ratio
  • IOVA N/A
  • DHC N/A
  • Revenue Growth
  • IOVA 636.99
  • DHC 4.29
  • 52 Week Low
  • IOVA $1.64
  • DHC $2.00
  • 52 Week High
  • IOVA $12.51
  • DHC $4.65
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 53.84
  • DHC 48.43
  • Support Level
  • IOVA $2.13
  • DHC $4.05
  • Resistance Level
  • IOVA $2.31
  • DHC $4.27
  • Average True Range (ATR)
  • IOVA 0.13
  • DHC 0.13
  • MACD
  • IOVA 0.02
  • DHC -0.04
  • Stochastic Oscillator
  • IOVA 72.97
  • DHC 35.56

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.

Share on Social Networks: